ABCG2 and cancer: Similarly, HS-173 at the same concentration did not re-sensitize ABCG2-overexpressing S1-MI-80 cancer cells to the drug substrates of ABCG2 (mitoxantrone, topotecan or SN-38) [64,65,66].